Peter Alping
YOU?
Author Swipe
View article: Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis Open
Few controlled trials of disease-modifying therapies (DMTs) have been conducted on the pediatric-onset multiple sclerosis (PoMS) population, leading to extensive off-label use of therapies approved only for adults. This highlights the need…
View article: Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis
Hospital‐Treated Infections and Risk of Disability Worsening in Multiple Sclerosis Open
Objective To investigate the association between infections and disability worsening in people with multiple sclerosis (MS) treated with either B‐cell depleting therapy (rituximab) or interferon‐beta/glatiramer acetate (IFN/GA). Methods Th…
View article: <scp>COMBAT</scp>‐<scp>MS</scp>: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
<span>COMBAT</span>‐<span>MS</span>: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab Open
Objective To assess comparative effectiveness, safety, and tolerability of off‐label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS). Methods A Swedish cohort study of persons with relapsing–remittin…
View article: Issue Information
Issue Information Open
OARE initiatives.They are now collectively known as Research4Life, making online scientific content available free or at nominal cost to researchers in developing countries and enabling more researchers to publish open access by providing
View article: Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study
Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study Open
Objective Although off‐label use of rituximab is a common alternative to disease‐modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this on treatment cost‐effectiveness is not well known. Me…
View article: Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study Open
PCORI identified multiple sclerosis (MS) as an important research topic.People with MS, clinicians, and others wanted to learn how different treatment strategies, aimed at changing specific symptoms or the overall course of MS, affect pati…
View article: Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab
Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab Open
Background Treatment for multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, has changed drastically in the last 30 years. Several different disease‐modifying therapies are now available, with off‐label u…
View article: Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study Open
Background: There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes. Objective: The aim of this study was to determine the association between MS and risks of adverse pregn…
View article: Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis Open
This study provides Class III evidence of an increased risk of thyroid disease with alemtuzumab and an increased risk of infection with AHSCT treatment.
View article: Issue Information
Issue Information Open
Canada & Mexico), €1375.00(Europe), £1090.00(UK), US$2131.00 (Rest of World).Prices are exclusive of tax.Asia-Pacific GST,
View article: Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients Open
Objective Novel, highly effective disease‐modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking. Methods In thi…
View article: Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Open
Patients with MS are at a generally increased risk of infections, and this differs by treatment. The rate of infections was lowest with interferon beta and GA; among newer treatments, off-label use of rituximab was associated with the high…
View article: Validation of the Swedish Multiple Sclerosis Register
Validation of the Swedish Multiple Sclerosis Register Open
The Swedish Multiple Sclerosis Register is a national register monitoring treatment and clinical course for all Swedish multiple sclerosis (MS) patients, with high coverage and close integration with the clinic. Despite its great value for…
View article: Rituximab in multiple sclerosis
Rituximab in multiple sclerosis Open
This study provides Class IV evidence that for patients with MS, rituximab is safe and effective.